Form 4: BioXcel Therapeutics Director Acquires Stock Options

Director Sandeep Laumas acquired 17,000 stock options in BioXcel Therapeutics on June 10, 2024.

Summary

• On June 10, 2024, Sandeep Laumas, a director of BioXcel Therapeutics, Inc. (BTAI), acquired 17,000 stock options.
• The options have an exercise price of $1.44.
• The options vest on the earlier of the first anniversary of the grant date or the day before the next annual meeting of the Issuer's stockholders, subject to continued service as a non-employee director.
• The expiration date for the options is June 10, 2034.
• Following the transaction, Laumas directly owns 17,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director, which is a common practice.

Positives

• The acquisition of stock options by a director signals confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders.

Key Dates

Keywords

BioXcel Therapeutics, BTAI, stock options, director, Sandeep Laumas, Form 4, acquisition